Figure 3.

PLCε knockdown sensitizes CRPC cells to enzalutamide in vitro and in vivo. (A) LNCaP, 22RV1and EN-R cells were exposed to increasing concentrations of enzalutamide for 48 h, and the IC₅₀ was determined by CCK-8 assay. (B and C) 22RV1 and EN-R cells were exposed to increasing concentrations of enzalutamide for 48 h, and the IC₅₀ of 22RV1 and EN-R cells following treatment with LV-shPLCε and/or GANT61 10 µM was determined by CCK-8 assay. (D) Tumors sizes. (E) Dynamic growth of implanted tumors in mice (*P<0.05; **P<0.01). PLCε, phospholipase Cε; CRPC, castration-resistant prostate cancer; EN-R, enzalutamide-resistant cell line; IC₅₀, half maximal inhibitory concentration; CCK-8, Cell Counting Kit-8; Enz, enzalutamide.